Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海复星医药(集团)股份有限公司是一家从事医药生物行业投资控股型公司,其主要业务有医疗器械、医药工商业及其他,通过其附属公司和联营企业经营药品生产及药品批发、零售业务.公司主要产品有西药类药品、中药类药品.公司已经取得肝病药物、妇科药物、糖尿病药物、临床诊断产品、口腔治疗机等细分市场领先地位.此外,公司还拥有金象大药房、复星大药房、国大药房、上海药房等药品零售品牌.2010年公司相继荣获第六届"金圆桌奖优秀董事会奖"、第二届"中国最具竞争力医药上市公司20强"等奖项。
Main Business 制药、医疗器械与医学诊断、医疗健康服务
Legal Representative 吴以芳
Top Executives
董事长：吴以芳
副董事长：关晓晖
执行董事：关晓晖,文德镛,吴以芳
非执行董事：陈玉卿,陈启宇,潘东辉,徐晓亮
独立非执行董事：汤谷良,王全弟,李玲,余梓山
Top 5 Shareholder
Shareholder name Nature Holding Date
上海复星高科技（集团）有限公司流通A股33.30%30/09/2024
HKSCCNOMINEESLIMITED注2H股20.63%30/09/2024
香港中央结算有限公司流通A股2.24%30/09/2024
中国证券金融股份有限公司流通A股1.45%30/09/2024
中国工商银行股份有限公司—华泰柏瑞沪深300交易型开放式指数证券投资基金流通A股0.89%30/09/2024
Company Secretary 卢绮霞
Solicitors 国浩律师（上海）事务所
Auditors 安永华明会计师事务所（特殊普通合伙）
Tel No 021-33987870
Fax No 021-33987871
Website www.fosunpharma.com
Email ir@fosunpharma.com
Company Address
Register: 上海市曹杨路510号9楼
Office: 上海市宜山路1289号A楼
Listing Date 07/08/1998
Shares Capital
Shares Capital: 2,671,326,465
Total A Share: 2,119,385,965
Listed A Share: 2,118,488,825
Non-tradable A Share: 897,140
Other Share: 0
Total B Share: 0
Total H Share: 551,940,500
EPS(RMB)* ¥ 0.890
DPS(RMB)* ¥ 0.270
NBV Per Share(RMB)* ¥ 17.110
Market Capitalization(RMB) 56.352B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.